🚀 VC round data is live in beta, check it out!
Valerio Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Valerio Therapeutics and similar public comparables like Verrica Pharmaceuticals, Cinclus Pharma Holding, Seres Therapeutics, Botanix Pharmaceuticals and more.
Valerio Therapeutics Overview
About Valerio Therapeutics
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.
Founded
1997
HQ
Employees
21
Website
Sectors
Financials (FY)
EV
$104M
Valerio Therapeutics Financials
Valerio Therapeutics reported last fiscal year revenue of $2M and negative EBITDA of ($14M).
In the same fiscal year, Valerio Therapeutics generated $1M in gross profit, ($14M) in EBITDA losses, and had net loss of ($27M).
Valerio Therapeutics P&L
In the most recent fiscal year, Valerio Therapeutics reported revenue of $2M and EBITDA of ($14M).
Valerio Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 71% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($14M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (673%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (920%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($27M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (1335%) | XXX | XXX | XXX |
| Net Debt | — | — | $13M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Valerio Therapeutics Stock Performance
Valerio Therapeutics has current market cap of $85M, and enterprise value of $104M.
Market Cap Evolution
Valerio Therapeutics' stock price is $0.17.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $104M | $85M | -0.6% | XXX | XXX | XXX | $-0.05 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialValerio Therapeutics Valuation Multiples
Valerio Therapeutics trades at 50.4x EV/Revenue multiple, and (7.5x) EV/EBITDA.
Valerio Therapeutics Financial Valuation Multiples
As of March 21, 2026, Valerio Therapeutics has market cap of $85M and EV of $104M.
Equity research analysts estimate Valerio Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Valerio Therapeutics has a P/E ratio of (3.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $85M | XXX | $85M | XXX | XXX | XXX |
| EV (current) | $104M | XXX | $104M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 50.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (7.5x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (5.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 70.6x | XXX | XXX | XXX |
| P/E | — | XXX | (3.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Valerio Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Valerio Therapeutics Margins & Growth Rates
Valerio Therapeutics' revenue in the last fiscal year declined by (0%).
Valerio Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (0%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (673%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (35%) | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 148% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 287% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 991% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Valerio Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Verrica Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Cinclus Pharma Holding | XXX | XXX | XXX | XXX | XXX | XXX |
| Seres Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Botanix Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Faron Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Valerio Therapeutics M&A Activity
Valerio Therapeutics acquired XXX companies to date.
Last acquisition by Valerio Therapeutics was on XXXXXXXX, XXXXX. Valerio Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Valerio Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialValerio Therapeutics Investment Activity
Valerio Therapeutics invested in XXX companies to date.
Valerio Therapeutics made its latest investment on XXXXXXXX, XXXXX. Valerio Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Valerio Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Valerio Therapeutics
| When was Valerio Therapeutics founded? | Valerio Therapeutics was founded in 1997. |
| Where is Valerio Therapeutics headquartered? | Valerio Therapeutics is headquartered in France. |
| How many employees does Valerio Therapeutics have? | As of today, Valerio Therapeutics has over 21 employees. |
| Is Valerio Therapeutics publicly listed? | Yes, Valerio Therapeutics is a public company listed on Euronext Paris. |
| What is the stock symbol of Valerio Therapeutics? | Valerio Therapeutics trades under ALVIO ticker. |
| When did Valerio Therapeutics go public? | Valerio Therapeutics went public in 2005. |
| Who are competitors of Valerio Therapeutics? | Valerio Therapeutics main competitors are Verrica Pharmaceuticals, Cinclus Pharma Holding, Seres Therapeutics, Botanix Pharmaceuticals. |
| What is the current market cap of Valerio Therapeutics? | Valerio Therapeutics' current market cap is $85M. |
| What is the current revenue of Valerio Therapeutics? | Valerio Therapeutics' last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of Valerio Therapeutics? | Current revenue multiple of Valerio Therapeutics is 50.4x. |
| Is Valerio Therapeutics profitable? | No, Valerio Therapeutics is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.